Communiqués Alvotech NYSE

Actions

ALVO

LU2458332611

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
5,750 ^USD	-2,21%		-2,04%	-38,70%

24/09	Actions nordiques en Amérique du Nord : Astra Zeneca a reculé de 1,2 %	FW
22/09	Actions nordiques en Amérique du Nord - Ericsson progresse de 0,4 %	FW

Communiqués

07/09	Takeda Files BPCIA Suit Against Alvotech For Vedolizumab Biosimilar	AQ
31/08	Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations	GL
27/08	Alvotech to present at upcoming investor conferences in September	GL
24/08	Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets	AQ
24/08	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets	AQ
21/08	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets	GL
19/08	Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update	GL
10/08	Alvotech to Report Financial Results for H1 2026	GL
29/07	Alvotech announces successful closure of FDA inspection of manufacturing facility	GL
29/07	Alvotech announces successful closure of FDA inspection of manufacturing facility	AQ
03/07	Transactions of Managers and Closely Associated Persons	GL
02/07	Janssen Files BPCIA Complaint Against Alvotech Related To Golimumab Biosimilar	AQ
01/07	Alvotech further strengthens liquidity by securing term loan facility of $75 million	GL
23/06	Transactions of Managers and Closely Associated Persons	GL
18/06	Alvotech’s BLA For Vedolizumab Biosimilar First To Be Accepted By FDA	AQ
18/06	Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement	GL
16/06	Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement	GL
15/06	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares	GL
10/06	Transactions of Managers and Closely Associated Persons	GL
08/06	Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®	GL
04/06	Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®	GL
03/06	Main Results of 2026 Annual and Extraordinary General Meeting	GL
02/06	Alvotech to present at upcoming investor conferences in June	GL
01/06	Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland	GL
11/05	Alvotech announces completion of FDA surveillance inspection at Reykjavik facility	GL